Loading data for ADIL — first visit, this takes a few seconds.

Alerte

Adial Pharmaceuticals Inc... (ADIL)

NasdaqCM: ADIL · Prix en temps réel · USD

4.39

+0.08 (1.86%)

À la clôture : Aug 18, 2026, 3:59 PM

1.86% (1D)

Cours acheteur	4.57
Capitalisation boursière	14.31M
Chiffre d’affaires (ttm)	n/a
Résultat net (ttm)	-57.8M
Bêta	n/a
EPS (ttm)	-5.39
Ratio P/E (ttm)	n/a
P/E prévisionnel	-0.73
P/B (ttm)	-0.37
P/S (ttm)	n/a
Earnings Date	n/a

Cours vendeur	3.08
Volume	51,676
Volume moy. (20D)	458,140
Ouverture	4.35
Clôture précédente	4.31
Fourchette du jour	4.26 - 4.63
Intervalle de 52 semaines	1.31 - 10.75
Analyste	n/a
Objectif de prix	n/a
Dividendes	n/a
Date ex-dividende	n/a

À propos de ADIL

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The...

[En savoir plus]

Industrie Biotechnology

Secteur Healthcare

Date d’introduction Jul 27, 2018

Employés 5

Bourse NasdaqCM

Symbole boursier ADIL

Site web https://www.adial.com

Profil complet de l’entreprise

Performance financière

En 2025, le chiffre d’affaires de Adial Pharmaceuticals s’élevait à 0, soit une hausse de undefined% par rapport aux 0 de l’année précédente. Le bénéfice s’élevait à -7.98M, soit une baisse de -39.56%.

États financiers

Surprise sur les résultats

Adial Pharmaceuticals a publié ses résultats trimestriels le May 8, 2026 :

Chiffre d’affaires de $0 est inférieur aux estimations de $0, avec NaN% croissance en glissement annuel.

EPS de -1.48 dépasse les estimations de 0.77, avec 82.59% croissance en glissement annuel.

Actualités

2 mois il y a · MT Newswires

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index and the State Street

2 mois il y a · Stocktwits

ADIL Stock Eyes Best Day In Over 5 Years — Major Pipeline Overhaul And $64M Raise Fuel Rally

Adial on Thursday announced that it has bought privately held Azora Therapeutics.

7 mois il y a · Zacks

Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?

Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.

10 mois il y a · The Fly

CoreWeave initiated, Instacart downgraded: Wall Street's top analyst calls

11 mois il y a · Benzinga

Adial Pharmaceuticals Highlights Favorable Comments From FDA Meeting For Lead Program In Alcohol Use Disorder

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) on Tuesday received the final meeting minutes from its End of Phase 2 (EOP2) Meeting with the U.S. Food and Drug Administration (FDA) held in July. The minute...

Page 1 de 2

Adial Pharmaceuticals Inc... (ADIL)